Hirahara I, Kusano E, Morishita Y, Inoue M, Akimoto T, Saito O, Muto S, Nagata D. Matrix metalloproteinase-2 as a superior biomarker for peritoneal deterioration in peritoneal dialysis. World J Nephrol 2016; 5(2): 204-212 [PMID: 26981446 DOI: 10.5527/wjn.v5.i2.204]
Corresponding Author of This Article
Dr. Ichiro Hirahara, Division of Nephrology, Department of Internal Medicine, Jichi Medical University, 3311-1 Yakushiji, Shimotsuke, Tochigi 329-0498, Japan. hirahara@rpf.jp
Research Domain of This Article
Urology & Nephrology
Article-Type of This Article
Observational Study
Open-Access Policy of This Article
This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
World J Nephrol. Mar 6, 2016; 5(2): 204-212 Published online Mar 6, 2016. doi: 10.5527/wjn.v5.i2.204
Table 1 Characteristics of peritoneal dialysis patients
Characteristics of patients
Sex (male/female)
122/96 (56% male)
Etiology (non-DM/DM)
179/36 (17% diabetes)
Age (yr)
56 (20, 46, 64, 84)
PD duration (mo)
40 (1, 15, 63, 206)
Peritonitis episode (times)
0 (0, 0, 1, 9)
D/P Cr
0.65 (0.38, 0.59, 0.71, 0.88)
D/D 0 glucose
0.40 (0.21, 0.34, 0.44, 0.59)
Table 2 Biomarker levels in the peritoneal effluent
Biomarker
Level in the peritoneal effluent
Matrix metalloproteinase-2 (ng/mL)
159 (14, 107, 220, 681)
Interleukin-6 (pg/mL)
14.6 (1.5, 7.6, 29.6, 253.5)
Hyaluronan (ng/mL)
109 (5.1, 53, 204, 889)
Cancer antigen 125 (U/mL)
6.7 (0.7, 4.0, 12.1, 91.8)
Table 3 Correlation between patient characteristics and effluent biomarker levels
Biomarker levels in the peritoneal effluents
MMP-2
IL-6
Hyaluronan
CA125
Sex (male/female)
P = 0.92
P = 0.54
P = 0.48
P < 0.05
Etiology (non-DM/DM)
P = 0.18
P = 1.00
P = 0.56
P < 0.05
Age (yr)
ρ = 0.076
ρ = 0.12
ρ = 0.046
ρ = -0.096
P = 0.27
P = 0.092
P = 0.50
P = 0.16
PD duration (mo)
ρ = 0.050
ρ = 0.15
ρ = 0.25
ρ = -0.062
P = 0.47
P < 0.05
P < 0.01
P = 0.93
Peritonitis episode (times)
ρ = 0.17
ρ = 0.25
ρ = 0.092
ρ = -0.012
P < 0.05
P < 0.001
P = 0.20
P = 0.86
Table 4 Correlation between effluent biomarker levels and the results of peritoneal equilibration test
D/P Cr
D/D0 glucose
MMP-2
IL-6
Hyaluronan
CA125
D/P Cr
ρ = 1
ρ = -0.86
ρ = 0.74
ρ = 0.46
ρ = 0.27
ρ = 0.13
P < 0.001
P < 0.001
P < 0.001
P < 0.001
P = 0.051
D/D0 Glucose
ρ = 1
ρ = -0.65
ρ = -0.28
ρ = -0.22
ρ = -0.094
P < 0.001
P < 0.001
P < 0.005
P = 0.19
MMP-2
ρ = 1
ρ = 0.54
ρ = 0.40
ρ = 0.1
P < 0.001
P < 0.001
P < 0.05
IL-6
ρ = 1
ρ = 0.45
ρ = 0.26
P < 0.001
P < 0.001
Hyaluronan
ρ = 1
ρ = 0.18
P < 0.01
CA125
ρ = 1
Table 5 Test performance of effluent biomarkers cut-off levels to distinguish the high category of peritoneal equilibration test
Biomarkers
Cut-off level
Sensitivity (95%CI)
Specificity (95%CI)
AUC
MMP-2-
214 ng/mL
0.95 (0.86 to 1.00)
0.79 (0.74 to 0.85)
0.90
219 ng/mL
0.86 (0.71 to 1.00)
0.81 (0.76 to 0.86)
228 ng/mL
0.81 (0.62 to 0.95)
0.84 (0.79 to 0.89)
238 ng/mL
0.76 (0.57 to 0.95)
0.87 (0.82 to 0.91)
IL-6
16.8 pg/mL
0.81 (0.62 to 0.95)
0.60 (0.53 to 0.67)
0.78
19.3 pg/mL
0.76 (0.57 to 0.90)
0.65 (0.58 to 0.73)
20.0 pg/mL
0.71 (0.52 to 0.90)
0.66 (0.60 to 0.73)
24.8 pg/mL
0.67 (0.48 to 0.86)
0.75 (0.66 to 0.79)
Hyaluronan
94.5 ng/mL
0.81 (0.62 to 0.95)
0.47 (0.41 to 0.54)
0.62
101.5 ng/mL
0.71 (0.52 to 0.90)
0.51 (0.44 to 0.58)
108.0 ng/mL
0.67 (0.48 to 0.86)
0.52 (0.45 to 0.58)
115.0 ng/mL
0.62 (0.43 to 0.81)
0.53 (0.46 to 0.53)
CA125
3.85 U/mL
0.81 (0.62 to 0.95)
0.23 (0.17 to 0.29)
0.51
4.45 U/mL
0.71 (0.52 to 0.90)
0.30 (0.23 to 0.37)
6.55 U/mL
0.62 (0.43 to 0.81)
0.50 (0.43 to 0.57)
7.05 U/mL
0.52 (0.33 to 0.71)
0.53 (0.46 to 0.59)
Table 6 Test performance of effluent matrix metalloproteinase-2 cut-off levels to predict the encapsulating peritoneal sclerosis in peritoneal dialysis patients
Cut-off level
Sensitivity (95%CI)
Specificity (95%CI)
AUC
458.5
1.00 (1.00 to 1.00)
0.96 (0.94 to 0.98)
0.99
609.5
0.88 (0.63 to 1.00)
0.99 (0.98 to 1.00)
863.5
0.63 (0.25 to 0.88)
1.00 (0.99 to 1.00)
Citation: Hirahara I, Kusano E, Morishita Y, Inoue M, Akimoto T, Saito O, Muto S, Nagata D. Matrix metalloproteinase-2 as a superior biomarker for peritoneal deterioration in peritoneal dialysis. World J Nephrol 2016; 5(2): 204-212